Key data from the 11th international workshop on adverse drug reactions and co-morbidities in HIV

Antiviral Therapy

Volumn 14, Issue 8, 2009, Pages 1195-1208

  Boehme, Richard E ^a   Cameron, Stephen ^b  

^a International Medical Press   (United States)

^b International Medical Press   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIDANOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EXENDIN 4; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SALSALATE; STAVUDINE; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; ZIDOVUDINE;

ACUTE KIDNEY TUBULE NECROSIS; ADIPOSE TISSUE; AEROBIC CAPACITY; AGING; BONE DENSITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONFERENCE PAPER; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; EXERCISE; FANCONI RENOTUBULAR SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; LIPOATROPHY; LIPODYSTROPHY; LONG TERM CARE; METABOLIC DISORDER; MICROALBUMINURIA; MONOTHERAPY; NONHUMAN; OSTEOPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SMOKING CESSATION; VITAMIN D DEFICIENCY; WEIGHT REDUCTION;

AGE FACTORS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE AND BONES; CARDIOVASCULAR DISEASES; DRUG TOXICITY; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; TREATMENT OUTCOME;

EID: 73449122258     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1470     Document Type: Conference Paper

References (59)

1. Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004; 170:229-238.
2. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
3. Bacchetti P, Grunfeld C, Heymsfield SB, et al. Intermuscular adipose tissue is decreased in HIV infection. Antivir Ther 2009; 14 Suppl 2:A3.
4. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121-131.
5. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection J Acquir Immune Defic Syndr 2006; 42:562-571.
6. Puls RL, Srasuebkul P, Petoumenos K, Emery S, Cooper DA. Anthropometric and metabolic outcomes in a 48-week randomized, open-label study of three different combination antiretroviral regimens as initial therapy for HIV infection. Antivir Ther 2009; 14 Suppl 2:A8.
7. Ionescu G, Walker R, He Q, Albu JB, Engelson ES, Kotler DP. Effect of substituting tenofovir for zidovudine versus continuing zidovudine on physiological correlates of mitochondrial function in HIV-infected subjects on nucleoside reverse transcriptase inhibitor therapy (NRTI)-based highly active antiretroviral therapy (HAART) - final report. Antivir Ther 2009; 14 Suppl 2:A17.
8. Vrouenraets SME, Fernandez Garcia E, Jackson A, et al. Both once-daily saquinavir/ritonavir and atazanavir/ritonavir, when combined with tenofoviar/emtricitabine conserve adipose tissue, only modestly affect lipids and exhibit similar mild reduction in glomerular filtration over 48 weeks: the BASIC trial. Antivir Ther 2009; 14 Suppl 2:A27.
9. Podzamczer D, Soriano V, Andrade-Villanueva J, et al. Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naive HIV-1-infected patients: ARTEN study week 48 results. Antivir Ther 2009; 14 Suppl 2:A51.
10. Alam NM, Cortina-Borja M, Goetghebuer T, Vigano A, Thorne C. Risk factors for body fat redistribution in a European cohort of HIV-infected children and adolescents. Antivir Ther 2009; 14 Suppl 2:A27.
11. Gathercole LL, Tomlinson JW, Boothby M, et al. Changes in the adipocyte (lipid and glucose metabolism) gene expression following 18-24 months treatment with ZDV or TDF-containing ART; and adipocyte mitochondrial gene expression. Antivir Ther 2009; 14 Suppl 2:A9.
12. McGee KC, Boothby M, Tomlinson JW, et al. Adipocyte mitochondrial gene expression following 18-24 months treatment with zidovidine or tenofovir-containing antiretroviral therapy. Antivir Ther 2009; 14 Suppl 2:A10.
13. Distler O, Mallon PW, Kelleher AD, Carr A, Calmy A, Cooper DA. Evaluation of adipose gene expression and mitochondrial DNA in healthy adults over a 6 week course of NRTI and/or PI treatment. Indications of divergent effects. Antivir Ther 2009; 14 Suppl 2:A10.
14. Martone S, Milazzo L, Cellerino P, et al. mRNA expression profile of adipocytes cells in HIV-1-positive with HAART-related lipodistrophy. Antivir Ther 2009; 14 Suppl 2:A23.
15. Stankov MV, Schmidt RE, Behrens GMN. Combined impact of C-reactive protein and stavudine on adipogenesis. Antivir Ther 2009; 14 Suppl 2:A11.
16. Yuan G, Chen X, Ma Q, et al. C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J Endocrinol 2007; 194:275-281.
17. Shikuma CM, Gerschenson LE, Kruse CA, et al. Preadipocyte apoptosis and macrophages in subcutaneous adipose tissue contribute to HIV-associated lipoatrophy. Antivir Ther 2009; 14 Suppl 2:A23.
18. Veloso S, Sirvent JJ, López-Dupla M, et al. Subcutaneous adipose tissue adipocyte apoptotic parameters in HIV-1-infected patients with HAART-related lipoatrophy. Antivir Ther 2009; 14 Suppl 2:A24.
19. Lo J, You SM, Wei J, Canavan B, Grinspoon S. Relationship of peak growth hormone to cardiovascular parameters, waist circumference, lipids and glucose in HIV-infected patients and healthy adults. Clin Endocrinol (Oxf) 2009; 71:815-822.
20. Lo J, You SM, Liebau J, et al. Effects of treatment and discontinuation of low dose physiologic growth hormone in HIV patients with abdominal fat accumulation: a randomized, placebo-controlled 36-month crossover trial. Antivir Ther 2009; 14 Suppl 2:A3.
21. Falutz J, Mamputu J-C, Potvin Soulban G, Grinspoon S. Metabolic effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in HIV-infected patients with excess abdominal fat. a pooled analysis of 2 multicenter, double-blind placebo-controlled Phase 3 trials with 816 randomized patients. 18th Annual Canadian Conference on HIV/AIDS Research. 23-26 April 2009, Vancouver, BC, Canada. Abstract O070.
22. Turner RR, McColl SL, Falutz J, et al. The impact and clinical relevance of tesamorelin (TH9507), a growth hormone-releasing factor analogue, on belly and weight image and healthrelated quality of life (HRQOL) in HIV-infected patients with excess abdominal fat: a combined analysis of two Phase III studies. Antivir Ther 2009; 14 Suppl 2:A4.
23. Bastard J-P, Bouteloup V, Leport C, et al. High incidence and risk factors for diabetes over the 9-year follow-up after first generation protease inhibitors' initiation in the ANRS CO8 APROCO-COPILOTE cohort. Antivir Ther 2009; 14 Suppl 2:A5.
24. Brown TT, Tassiopoulos K, Shikuma C, McComsey GA. Higher markers of TNF-α activity 48 weeks after ART-initiation are associated with incident diabetes mellitus in the ACTG/ALLRT cohort: a nested case-control study. Antivir Ther 2009; 14 Suppl 2:A6.
25. Kim PS, Woods C, Dutcher L, et al. Increased microalbuminuria in HIV-infected adults with diabetes is associated with abacavir and viral load. Antivir Ther 2009; 14 Suppl 2:A7.
26. Schuster I, Thöni GJ, Edéry S, et al. Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy. Am J Cardiol 2008; 101:1213-1217.
27. Hruz PW, Yan Q, Struthers H, Jay PY. HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy. FASEB J 2008; 22:2161-2167.
28. Vyas AK, Yang K-C, Woo D, Jay PY, Hruz PW. Beneficial effect of exenatide on glucose homeostasis and survival in ritonavir-treated mice with advanced dilated cardiomyopathy. Antivir Ther 2009; 14 Suppl 2:A7.
29. Fleischman A, Johnsen S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007; 292:E1666-E1673.
30. Saeedi R, Saran V, Johns K, et al. Stavudine alters expression of adipocyte-derived adipocytokines and promotes insulin resistance in cultured adipocytes. Antivir Ther 2009; 14 Suppl 2:A25.
31. Ganz P. Non-invasive assessment of atherosclerosis - are measurements of endothelial function and carotid IMT useful? 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. 26-28 October 2009, Philadelphia, PA, USA. Available from http://broadcast.sztream.com/1515174/ lipo2009/Index.html
32. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315:1046-1051.
33. Guaraldi G, Zona S, Orlando G, et al. Progression of subclinical atherosclerosis in HIV-infected patients. Antivir Ther 2009; 14 Suppl 2:A11.
34. Richardson R, Sinn K, Cooper DA, Patt S, Carr A. Arterial stiffness and cardiovascular biomarkers in HIV-infected adults. Antivir Ther 2009; 14 Suppl 2:A12.
35. Young B, Vanig T, DeJesus E, et al. Framingham risk and lipoprotein changes after 24 weeks of treatment with abacavir/lamivudine (ABC/3TC) and raltegravir (RAL) in antiretroviral (ARV)-naive HIV-1-infected subjects. Antivir Ther 2009; 14 Suppl 2:A54.
36. Hileman CO, Carman TL, Gripshover BM, et al. Salsalate is poorly tolerated and fails to improve endothelial function and insulin resistance in virologically suppressed HIV-infected patients. Antivir Ther 2009; 14 Suppl 2:A13.
37. 2 HIV): a cohort study. Lancet 2002; 360:368-373.
38. Cade WT, Holland MR, Stephens AS, et al. Decreased myocardial longitudinal strain in HIV-negative neonates exposed to HIV and HAART in utero. Antivir Ther 2009; 14 Suppl 2:A13.
39. Rader D. Inflammation and atherosclerosis. Presented at: 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. 26-28 October 2009, Philadelphia, PA, USA.
40. Cotter EJ, Chew N, Powderly WG, Doran PP. Ex vivo infection of mesenchymal stem cells by HIV-1 alters differentiation potential and cell phenotype. Antivir Ther 2009; 14 Suppl 2:A14.
41. Moyle G, Givens N, Pearce H, Compston J. Effects of ART on bone turnover markers and bone density in HIV-infected patients. Antivir Ther 2009; 14 Suppl 2:A14.
42. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
43. Welz T, Childs K, Ibrahim F, Poulton M, Post F. Efavirenz use is associated with severe vitamin D deficiency in a large, ethnically diverse urban UK HIV cohort. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 2009, Cape Town, South Africa. Abstract TUPEB186.
44. Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther 2009; 14 Suppl 2:A15.
45. Effros RB, Graham LS, Parhami F, Tintut Y. T-lymphocytes and bone loss in HIV disease: role of chronic stimulation and oxidized lipids. Antivir Ther 2009; 14 Suppl 2:A16.
46. Falutz J, Rosenthall L. FRAX score: fracture risk assessment in treated HIV patients. Antivir Ther 2009; 14 Suppl 2:A31.
47. Guaraldi G, Zona S, Vescini F, et al. Gender and gonadal function differences in the prevalence of bone mass reduction. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 754.
48. Liu A, Gvetadze R, Sellmeyer D, Grohskopf L, Buchbinder S. Low bone density among a population of healthy HIV-negative MSM screening for a pre-exposure prophylaxis trial. XVII International AIDS Conference. 3-8 August 2008, Mexico City, Mexico. Abstract THPE0169.
49. Glover E, Martin J, Mocellin NJ, Elston D, Smaill F, Tarnopolsk MA. Exercise capacity and markers of mitochondrial function in HIV-infected patients on NRTI therapy. Antivir Ther 2009; 14 Suppl 2:A61.
50. Hulgan T, Haubrich R, Riddler S, et al. Mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy (ART) in AIDS Clinical Trials Group (ACTG) Study A5142. Antivir Ther 2009; 14 Suppl 2:A17.
51. Arenas-Pinto A, Weller I, Ekong R, et al. Dideoxynucleoside- induced severe hyperlactataemia in white Europeans appears not to be caused by a common inherited mtDNA mutation. Antivir Ther 2009; 14 Suppl 2:A65.
52. Lebrecht D, Venhoff AC, Kirschner J, Venhoff N, Walker UA. Mitochondrial toxicity depletes primarily slow muscle fibres in zidovudine-induced myopathy. Antivir Ther 2009; 14 Suppl 2:A63.
53. Blas-García A, Victor VM, Gómez-Soler M, Gómez-Sucerquia LJ, Apostolova N, Espulgues JV. EFV-induced reduction of mitochondrial respiration is due to the inhibition of complex I. Antivir Ther 2009; 14 Suppl 2:A61.
54. Campisi J. Ageing: the ultimate co-morbidity factor. Presented at: 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. 26-28 October 2009, Philadelphia, PA, USA. Available from http://broadcast.sztream.com/1515174/lipo2009/Index.html
55. Cotter EJ, Powderly WG, Doran PP. Tenofovir putatively induces fibrosis in cultured human proximal tubule epithelial cells. Antivir Ther 2009; 14 Suppl 2:A18.
56. Brown TT, Patil SP, Jacobson LP, et al. Association between systemic inflammation and obstructive sleep apnea in men with or at risk for HIV infection from the Multicenter AIDS Cohort Study (MACS). Antivir Ther 2009; 14 Suppl 2:A19.
57. Jahanshad N, Shikuma CM, Kallianpur K, Nakamoto B, Valcour VG, Thompson PM. Impact of cerebrovascular risk factors on brain function and structure in HIV-infected individuals. Antivir Ther 2009; 14 Suppl 2:A5.
58. Biggar R. Does immunity control the expression of cancer? Learning from the experience of the HIV/AIDS epidemic. Presented at: 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. 26-28 October 2009, Philadelphia, PA, USA. Available from http://broadcast.sztream.com/ 1515174/lipo2009/Index.html
59. Sarrazin C. New antiviral drugs against HCV - adverse event profiles and pharmacokinetic interactions. Presented at: 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. 26-28 October 2009, Philadelphia, PA, USA. Available from http://broadcast.sztream.com/1515174/ lipo2009/Index.html